<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 21, 2026 at 11:35 PM by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Sat, 21 Nov 2026 05:11:25 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/nanoscope-therapeutics-partners-with-uniphar-for-mogenry/]]></guid>
			<link><![CDATA[https://cgxpwire.com/nanoscope-therapeutics-partners-with-uniphar-for-mogenry/]]></link>
			<title>Nanoscope Therapeutics Partners with Uniphar for MOGENRY</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 05:11:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/merck-reports-positive-phase-3-survival-results-for-sac-tmt/]]></guid>
			<link><![CDATA[https://cgxpwire.com/merck-reports-positive-phase-3-survival-results-for-sac-tmt/]]></link>
			<title>Merck Reports Positive Phase 3 Survival Results for Sac-TMT</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 05:02:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/belite-bio-reports-fda-review-extension-for-tinlarebant/]]></guid>
			<link><![CDATA[https://cgxpwire.com/belite-bio-reports-fda-review-extension-for-tinlarebant/]]></link>
			<title>Belite Bio Reports FDA Review Extension for Tinlarebant</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:59:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/johnson-johnson-installs-first-commercial-ottava-surgical-robot/]]></guid>
			<link><![CDATA[https://cgxpwire.com/johnson-johnson-installs-first-commercial-ottava-surgical-robot/]]></link>
			<title>Johnson &amp; Johnson Installs First Commercial OTTAVA Surgical Robot</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:56:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/savara-reports-fda-delay-for-molgramostim-bla-review/]]></guid>
			<link><![CDATA[https://cgxpwire.com/savara-reports-fda-delay-for-molgramostim-bla-review/]]></link>
			<title>Savara Reports FDA Delay for Molgramostim BLA Review</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:52:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/erasca-reports-promising-phase-1-results-for-eras-0015/]]></guid>
			<link><![CDATA[https://cgxpwire.com/erasca-reports-promising-phase-1-results-for-eras-0015/]]></link>
			<title>Erasca Reports Promising Phase 1 Results for ERAS-0015</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:49:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/caliway-secures-china-clinical-clearance-for-cbl-514/]]></guid>
			<link><![CDATA[https://cgxpwire.com/caliway-secures-china-clinical-clearance-for-cbl-514/]]></link>
			<title>Caliway Secures China Clinical Clearance for CBL-514</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:45:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/actinogen-reports-older-patient-findings-in-alzheimers-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/actinogen-reports-older-patient-findings-in-alzheimers-trial/]]></link>
			<title>Actinogen Reports Older-Patient Findings in Alzheimer&#8217;s Trial</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:41:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/innovative-health-wins-fda-clearance-for-octaray-reprocessing/]]></guid>
			<link><![CDATA[https://cgxpwire.com/innovative-health-wins-fda-clearance-for-octaray-reprocessing/]]></link>
			<title>Innovative Health Wins FDA Clearance for OCTARAY Reprocessing</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:35:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/bristol-myers-squibb-highlights-hematology-advances-at-ash-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/bristol-myers-squibb-highlights-hematology-advances-at-ash-2026/]]></link>
			<title>Bristol Myers Squibb Highlights Hematology Advances at ASH 2026</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:23:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/gsk-wins-japan-orphan-drug-status-for-velzatinib-in-gist/]]></guid>
			<link><![CDATA[https://cgxpwire.com/gsk-wins-japan-orphan-drug-status-for-velzatinib-in-gist/]]></link>
			<title>GSK Wins Japan Orphan Drug Status for Velzatinib in GIST</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:22:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/johnson-johnson-seeks-fda-approval-for-caplyta-in-mania/]]></guid>
			<link><![CDATA[https://cgxpwire.com/johnson-johnson-seeks-fda-approval-for-caplyta-in-mania/]]></link>
			<title>Johnson &amp; Johnson Seeks FDA Approval for CAPLYTA in Mania</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:20:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/alnylam-and-regeneron-announce-fda-approval-of-livsayis-for-myasthenia-gravis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/alnylam-and-regeneron-announce-fda-approval-of-livsayis-for-myasthenia-gravis/]]></link>
			<title>Alnylam and Regeneron Announce FDA Approval of Livsayis for Myasthenia Gravis</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:16:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ambari-advances-plasma-exchange-study-for-alzheimers/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ambari-advances-plasma-exchange-study-for-alzheimers/]]></link>
			<title>AmBARI Advances Plasma Exchange Study for Alzheimer’s</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:06:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/marker-therapeutics-secures-16-2m-grant-for-mt-601/]]></guid>
			<link><![CDATA[https://cgxpwire.com/marker-therapeutics-secures-16-2m-grant-for-mt-601/]]></link>
			<title>Marker Therapeutics Secures $16.2M Grant for MT-601</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 04:01:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/human-dna-creates-faster-mouse-model-for-rare-disease-research/]]></guid>
			<link><![CDATA[https://cgxpwire.com/human-dna-creates-faster-mouse-model-for-rare-disease-research/]]></link>
			<title>Human DNA Creates Faster Mouse Model for Rare Disease Research</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 11:16:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lecanemab-shows-benefit-in-alzheimers-α-syn-substudy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lecanemab-shows-benefit-in-alzheimers-α-syn-substudy/]]></link>
			<title>Eisai and Biogen Report Lecanemab Benefits in Alzheimer’s α-Syn Substudy</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 11:07:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/celldex-ends-barzolvolimab-program-in-atopic-dermatitis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/celldex-ends-barzolvolimab-program-in-atopic-dermatitis/]]></link>
			<title>Celldex Ends Barzolvolimab Program in Atopic Dermatitis</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:40:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/anixa-biosciences-secures-canadian-patent-for-ovarian-cancer-vaccine/]]></guid>
			<link><![CDATA[https://cgxpwire.com/anixa-biosciences-secures-canadian-patent-for-ovarian-cancer-vaccine/]]></link>
			<title>Anixa Biosciences Secures Canadian Patent for Ovarian Cancer Vaccine</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:31:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/guardant-health-launches-ultra-sensitive-mrd-test/]]></guid>
			<link><![CDATA[https://cgxpwire.com/guardant-health-launches-ultra-sensitive-mrd-test/]]></link>
			<title>Guardant Health Launches Ultra-Sensitive MRD Test</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:27:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/astrazenecas-sone-ve-receives-fda-priority-review-for-gastric-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/astrazenecas-sone-ve-receives-fda-priority-review-for-gastric-cancer/]]></link>
			<title>AstraZeneca&#8217;s Sone-Ve Receives FDA Priority Review for Gastric Cancer</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:27:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ge-healthcare-advances-mangaciclanol-to-phase-3-after-positive-phase-2-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ge-healthcare-advances-mangaciclanol-to-phase-3-after-positive-phase-2-results/]]></link>
			<title>GE HealthCare Advances Mangaciclanol to Phase 3 After Positive Phase 2 Results</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:22:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/axoft-reports-clinical-progress-with-ultra-soft-brain-probes/]]></guid>
			<link><![CDATA[https://cgxpwire.com/axoft-reports-clinical-progress-with-ultra-soft-brain-probes/]]></link>
			<title>Axoft Reports Clinical Progress With Ultra-Soft Brain Probes</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:16:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/revolution-medicines-reports-promising-pancreatic-cancer-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/revolution-medicines-reports-promising-pancreatic-cancer-data/]]></link>
			<title>Revolution Medicines Reports Promising Pancreatic Cancer Data</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 10:00:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/neonc-reschedules-fda-meeting-to-advance-neo212/]]></guid>
			<link><![CDATA[https://cgxpwire.com/neonc-reschedules-fda-meeting-to-advance-neo212/]]></link>
			<title>NeOnc Reschedules FDA Meeting to Advance NEO212</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 09:57:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lupus-foundation-reports-promising-msc-therapy-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lupus-foundation-reports-promising-msc-therapy-results/]]></link>
			<title>Lupus Foundation Reports Promising MSC Therapy Results</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:09:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clarity-completes-amplify-follow-up-in-prostate-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clarity-completes-amplify-follow-up-in-prostate-cancer/]]></link>
			<title>Clarity Completes AMPLIFY Follow-Up in Prostate Cancer</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:03:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/abbott-launches-voyager-trial-for-encantor-heart-valve/]]></guid>
			<link><![CDATA[https://cgxpwire.com/abbott-launches-voyager-trial-for-encantor-heart-valve/]]></link>
			<title>Abbott Launches VOYAGER Trial for Encantor Heart Valve</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:59:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biohaven-reports-bhv-1530-responses-in-fgfr3-cancers/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biohaven-reports-bhv-1530-responses-in-fgfr3-cancers/]]></link>
			<title>Biohaven Reports BHV-1530 Responses in FGFR3 Cancers</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:56:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/astrazeneca-partners-to-advance-lupus-drug-development/]]></guid>
			<link><![CDATA[https://cgxpwire.com/astrazeneca-partners-to-advance-lupus-drug-development/]]></link>
			<title>AstraZeneca Partners to Advance Lupus Drug Development</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:55:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/johnson-johnson-installs-ottava-robotic-surgery-system/]]></guid>
			<link><![CDATA[https://cgxpwire.com/johnson-johnson-installs-ottava-robotic-surgery-system/]]></link>
			<title>Johnson &amp; Johnson Installs OTTAVA Robotic Surgery System</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:47:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/genprex-links-trop2-biomarker-to-reqorsa-lung-cancer-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/genprex-links-trop2-biomarker-to-reqorsa-lung-cancer-therapy/]]></link>
			<title>Genprex Links TROP2 Biomarker to REQORSA Lung Cancer Therapy</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:37:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/harbour-biomed-advances-ai-enabled-obesity-drug-let003/]]></guid>
			<link><![CDATA[https://cgxpwire.com/harbour-biomed-advances-ai-enabled-obesity-drug-let003/]]></link>
			<title>Harbour BioMed Advances AI-Enabled Obesity Drug LET003</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:34:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/adcendo-reports-positive-phase-1-data-for-adce-d01/]]></guid>
			<link><![CDATA[https://cgxpwire.com/adcendo-reports-positive-phase-1-data-for-adce-d01/]]></link>
			<title>Adcendo Reports Positive Phase 1 Data for ADCE-D01</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:27:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/evotec-and-bms-secure-second-fda-ind-acceptance/]]></guid>
			<link><![CDATA[https://cgxpwire.com/evotec-and-bms-secure-second-fda-ind-acceptance/]]></link>
			<title>Evotec and BMS Secure Second FDA IND Acceptance</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:20:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/regeneron-gains-fda-approval-for-livsayis-in-adult-gmg-care/]]></guid>
			<link><![CDATA[https://cgxpwire.com/regeneron-gains-fda-approval-for-livsayis-in-adult-gmg-care/]]></link>
			<title>Regeneron Gains FDA Approval for Livsayis in Adult gMG Care!</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:12:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/sanofi-wins-eu-approval-for-next-gen-rabies-vaccine/]]></guid>
			<link><![CDATA[https://cgxpwire.com/sanofi-wins-eu-approval-for-next-gen-rabies-vaccine/]]></link>
			<title>Sanofi Wins EU Approval for Next-Gen Rabies Vaccine</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:10:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/corsera-starts-phase-1-trial-of-cor-2003-rnai-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/corsera-starts-phase-1-trial-of-cor-2003-rnai-therapy/]]></link>
			<title>Corsera Starts Phase 1 Trial of COR-2003 RNAi Therapy</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 04:06:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/adagene-doses-first-patient-in-adg138-phase-1-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/adagene-doses-first-patient-in-adg138-phase-1-trial/]]></link>
			<title>Adagene Doses First Patient in ADG138 Phase 1 Trial</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 03:59:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/philips-launches-ai-imaging-platform-for-radiology-workflows/]]></guid>
			<link><![CDATA[https://cgxpwire.com/philips-launches-ai-imaging-platform-for-radiology-workflows/]]></link>
			<title>Philips Launches AI Imaging Platform for Radiology Workflows</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 03:56:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/hutchmed-presents-hmpl-a830-preclinical-cancer-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/hutchmed-presents-hmpl-a830-preclinical-cancer-data/]]></link>
			<title>HUTCHMED Presents HMPL-A830 Preclinical Cancer Data</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 16:18:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/teva-names-interim-rd-lead-as-eric-hughes-departs/]]></guid>
			<link><![CDATA[https://cgxpwire.com/teva-names-interim-rd-lead-as-eric-hughes-departs/]]></link>
			<title>Teva Names Interim R&amp;D Lead as Eric Hughes Departs</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 11:56:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/disco-and-abbvie-partner-on-and-gated-cancer-therapies/]]></guid>
			<link><![CDATA[https://cgxpwire.com/disco-and-abbvie-partner-on-and-gated-cancer-therapies/]]></link>
			<title>DISCO and AbbVie Partner on AND-Gated Cancer Therapies</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 11:55:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/vitrivax-raises-87m-to-advance-lyme-disease-vaccine/]]></guid>
			<link><![CDATA[https://cgxpwire.com/vitrivax-raises-87m-to-advance-lyme-disease-vaccine/]]></link>
			<title>VitriVax Raises $87M to Advance Lyme Disease Vaccine</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 11:39:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/asgard-secures-e2-5m-grant-to-advance-at-108-cancer-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/asgard-secures-e2-5m-grant-to-advance-at-108-cancer-therapy/]]></link>
			<title>Asgard Secures €2.5M Grant to Advance AT-108 Cancer Therapy</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 11:37:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pyxis-reports-durable-micvo-data-in-head-and-neck-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pyxis-reports-durable-micvo-data-in-head-and-neck-cancer/]]></link>
			<title>Pyxis Reports Durable MICVO Data in Head and Neck Cancer</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 11:12:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/recursion-aligns-fda-on-phase-3-rec-4881-trial-for-fap/]]></guid>
			<link><![CDATA[https://cgxpwire.com/recursion-aligns-fda-on-phase-3-rec-4881-trial-for-fap/]]></link>
			<title>Recursion Aligns FDA on Phase 3 REC-4881 Trial for FAP</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 11:11:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/acadia-reports-new-remlifanserin-data-in-alzheimers-psychosis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/acadia-reports-new-remlifanserin-data-in-alzheimers-psychosis/]]></link>
			<title>Acadia Reports New Remlifanserin Data in Alzheimer’s Psychosis</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 10:46:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/inovio-submits-ema-application-for-voceryq-in-rrp/]]></guid>
			<link><![CDATA[https://cgxpwire.com/inovio-submits-ema-application-for-voceryq-in-rrp/]]></link>
			<title>INOVIO Submits EMA Application for VOCERYQ in RRP</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 10:40:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/inspiremd-begins-first-u-s-commercial-cguard-prime-tcar/]]></guid>
			<link><![CDATA[https://cgxpwire.com/inspiremd-begins-first-u-s-commercial-cguard-prime-tcar/]]></link>
			<title>InspireMD Begins First U.S. Commercial CGuard Prime TCAR</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 10:36:23 +0000]]></pubDate>
		</item>
				</channel>
</rss>
